Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BCC Research analyzes innovations, trends, competition and regional opportunities shaping single-use technologies in biopharma manufacturing.
-
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
-
NEW YORK, 30 juill. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome...
-
MIRA advances MIRA-55 and SKNY-1 through exploratory toxicology, CMC and manufacturing activities supporting future IND-enabling studies.
-
Second-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling from...
-
Authorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE)...
-
SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...
-
PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
-
Successful initiation of the Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), one of Israel’s largest and most prominent academic medical centers, clears...
-
Lungpacer Medical today announced results from a new health economic analysis demonstrating national average cost savings of ~$24,000 per episode.